1. Spain Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Atrys Health, S.A.

Atrys Health, S.A.

ATRY.MC
Atrys Health, S.A.ES flagMadrid Stock Exchange
2.57
EUR
-0.01
- -
194.73MMarket Cap
Atrys Health, S.A.
ATRY.MC
(Madrid Stock Exchange)

Recent

price

2.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.13
0.13
0.13
0.35
0.42
0.56
0.37
0.69
1.11
2.41
2.32
2.66
1.71
- -
Revenue per Share
0.08
0.04
0.04
0.16
0.01
0.03
- -
- -
-0.2
-0.46
-0.34
-0.6
-0.42
- -
Basic EPS, GAAP
- -
- -
- -
- -
-0.22
-0.1
-0.16
-0.17
-0.24
-0.08
-0.45
-0.1
-0.13
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.08
0.04
0.04
0.17
0.03
0.04
0.01
0.01
-0.18
-0.48
-0.33
-0.59
-0.41
- -
Book Value per Share
-0.91
-1.18
-1.34
-1.8
-0.53
0.17
-0.03
-0.7
-1.87
-2.27
-2.68
-2.12
-2.25
- -
Tangible Book Value per Share
8
8
8
8
11
11
19
21
28
50
68
76
76
- -
Basic Weighted Avg Shares
1
1
1
3
5
6
7
15
31
121
158
202
130
141
Sales/Revenue/Turnover
7.37
-11.89
41.57
7.45
-2.13
11.95
9.68
8.02
-6.81
-10.24
-2.26
1.49
4.51
-4.07
Operating Margin (%)
- -
- -
- -
- -
1
1
1
2
6
21
26
30
29
27
Depreciation Expense
1
- -
- -
1
- -
- -
- -
- -
-6
-23
-23
-46
-32
-100
Net Income, GAAP
- -
- -
- -
- -
- -
- -
81.17
150.71
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
63.17
33.03
29.39
45.18
1.38
4.82
0.16
-0.71
-17.67
-19.22
-14.62
-22.62
-24.45
-71.13
Profit Margin (%)
4
3
2
- -
2
8
10
8
16
30
1
-3
-11
-56
Working Capital
10
11
11
12
1
10
15
30
60
137
210
190
196
34
LT Debt
- -
- -
- -
- -
10
19
26
40
71
273
336
290
253
152
Total Equity
- -
- -
- -
- -
- -
- -
0.34
-0.99
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
0.8
-2.36
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
65.56
96.3
153.7
7.5
73.94
3.45
-55.27
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.77%
-40%
Free Cash Flow
- -
129.44%
38.8%
Net Income, GAAP
499.19%
120.2%
215.65%
Sales/Revenue/Turnover
64.39%
63.31%
8.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
202
2024
- -
- -
- -
- -
130
2025
- -
- -
- -
- -
141

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.6
2024
- -
- -
- -
- -
-0.42
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
KALA BIO, Inc. (0JQ2.L)
NKGen Biotech, Inc. Warrants (NKGNW)
Biotest AG (BIO3.DE)
Energenesis Biomedical CO.,LTD. (6657.TW)
Polus BioPharm Inc. (007630.KS)
Nabriva Therapeutics plc (NBRVF)
Business
Atrys Health SA operates as a global healthtech company specializing in precision medical diagnosis and treatment services, with a focus on telemedicine, cancer care, and preventive medicine. The company provides integrated diagnostics including structural and molecular pathology, genetics, nuclear medicine, teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; oncology treatments encompassing chemotherapy, immunotherapy, advanced radiotherapy, brachytherapy, and teragnosis; preventive medicine plans for occupational risk prevention and employee health check-ups; and Smart Data technological databases for healthcare alongside research and development services. Atrys Health maintains diagnostic laboratories and translational research facilities in Barcelona and Granada, radiotherapy centers across Spain, Portugal, Switzerland, Mexico, Chile, Colombia, and Brazil, and over 400 healthcare centers in seven countries serving hospitals, insurers, corporates, and patients. Founded in 2007 and headquartered in Madrid, Spain, the company, formerly Althia Health SL until its rebranding in 2016, listed on BME Growth in 2016 and upgraded to the Main Market in 2022. Recent developments include the opening of the Institute of Advanced Oncology in Madrid, expansion of medical oncology centers in Mexico to five locations with two additional planned for late 2025, growth in genetics and pathology diagnostics, authorization for teragnosis services, and an agreement in November 2025 to sell its ASPY preventive business unit to Grupo Echevarne for 145 million euros to reduce net financial debt from 3.7x to around 1.0x EBITDA, yielding annual financial expense savings of 13 million euros.